Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CCL2 | P13500 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1173896 | 0.79 | MAPT (0.40) | — | |
| SCHEMBL1973187 | 0.76 | — | — | |
| SCHEMBL533162 | 0.76 | — | — | |
| SCHEMBL22683407 | 0.76 | BRD4 (0.35) | PTGS2BRD4CCL2PDE2APDE10A | |
| SCHEMBL20089414 | 0.75 | CHRNB2 (0.41) | BRD4CCL2PDE2APDE10A | |
| SCHEMBL20089009 | 0.74 | PTGS2 (0.38) | PTGS2BRD4CCL2 | |
| SCHEMBL533380 | 0.73 | LTA4H (0.39) | — | |
| SCHEMBL5949918 | 0.72 | NQO1 (0.43) | BRD4CCL2PDE2APDE10A | |
| SCHEMBL534050 | 0.72 | — | — | |
| SCHEMBL1976211 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10842803-B2 | Imidazopyridines Syk inhibitors | Kronos Bio, Inc. (US) | 2020-11-24 | — | — | US | claimed |
| US-20190117679-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Kronos Bio, Inc. | 2019-04-25 | — | — | US | claimed |
| US-20140148430-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2014-05-29 | — | — | US | claimed |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc (US) | 2013-08-15 | — | — | US | claimed |
| EP-2545052-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| WO-2011112995-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| US-11939317-B2 | Amide compounds and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| EP-4212523-A1 | PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20230115275-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| EP-3532465-B1 | PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2023-03-01 | — | — | EP | disclosed |
| CN-115531387-A | Pyrazole amide compounds useful as IRAK inhibitors | 里格尔药品股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| US-11530194-B2 | Amide compounds and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| CN-110234637-B | Pyrazole amide compounds useful as IRAK inhibitors | 里格尔药品股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2016172560-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20160311839-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| EP-2545052-B1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2014-11-12 | — | — | EP | disclosed |
| US-20140148430-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc (US) | 2013-08-15 | — | — | US | disclosed |
| EP-2545052-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011112995-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117679-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | PTGS2 1170/4885BRD4 686/4885CCL2 3245/4885 |
| US-20230115275-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | PTGS2 1496/4885BRD4 103/4885CCL2 328/4885 |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | PTGS2 1112/4885BRD4 667/4885CCL2 3257/4885 |
| US-20140148430-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | PTGS2 1112/4885BRD4 667/4885CCL2 3257/4885 |
| US-11939317-B2 | Amide compounds and method for making and using | IRAK1, IRAK2, IRAK3 | PTGS2 1496/4885BRD4 103/4885CCL2 328/4885 |
| US-10842803-B2 | Imidazopyridines Syk inhibitors | SYK, BTK, ZAP70 | PTGS2 1170/4885BRD4 686/4885CCL2 3245/4885 |
| US-20160311839-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | PTGS2 2088/4885BRD4 133/4885CCL2 1005/4885 |
| US-11530194-B2 | Amide compounds and method for making and using | IRAK1, IRAK2, IRAK3 | PTGS2 1496/4885BRD4 103/4885CCL2 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.